Type 2 diabetes subtypes

Alpha2 antagonists have relatively little clinical usefulness. There has been experimental interest in the development of highly selective antagonists for use in Raynaud s phenomenon to inhibit smooth muscle contraction and in the treatment of type 2 diabetes (n2 receptors inhibit insulin secretion) and psychiatric depression. It is not known to what extent the recognition of multiple subtypes of a2 receptors will lead to development of clinically useful subtype-selective new drugs. 

Type 1 diabetes, formerly known as childhood , juvenile or insulin-dependent diabetes, is not exclusively a childhood problem. Adults who contract type 1 diabetes may be misdiagnosed with type 2 diabetes. A subtype of type 1 (identifiable by the presence of antibodies against /3-cells) typically develops slowly and is often confused with type 2. In addition, a small proportion of type 1 cases have the hereditary condition maturity onset diabetes of the young (MODY), which can also be confused with type 2. 

More recent studies have confirmed that dual activation of PPARy and PPARo subtypes would be beneficial for treating type-2 diabetes [ 139]. In this connection KRP-297, a TZD derivative has been found to express in vitro as well as in vivo affinity for both the PPARo and PPARy subtypes [152], In light of this, Desai and co-workers have investigated the PPARoj/y dual agonistic activity of a series of TZD and oxazolidinedione derivatives (comp, a. Fig. 22, Table 14) to assess their antidiabetic activity [153,154],... 

---